Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment
Human Gene Therapy · 2023
DOI: 10.1089/hum.2023.028 ↗Kurz gefasst
Leserbrief in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Albert Qin. Beteiligte Einrichtung: Medical Research and Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan. Hauptthemen laut MEDLINE: Adenoviridae, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Research and Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan.
ORCID-Profile: Albert Qin
Zitieren
APA
Qin, A. (2023). Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment. Human Gene Therapy. https://doi.org/10.1089/hum.2023.028
Vancouver
Qin A. Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment. Human Gene Therapy. 2023. doi:10.1089/hum.2023.028
BibTeX
@article{Qin2023,
author = {Qin, Albert},
title = {Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment},
journal = {Human Gene Therapy},
year = {2023},
doi = {10.1089/hum.2023.028}
}
EUVIMED